PetMed Express, Inc. d/b/a 1-800-PetMeds Announces Its First Quarter Financial Results and a Quarterly Dividend of $0.30 Per Share
26 Julho 2021 - 9:00AM
PetMed Express, Inc. (NASDAQ: PETS) today announced its financial
results for its first quarter ended June 30, 2021. Net sales for
the quarter ended June 30, 2021 were $79.3 million, compared to
$96.2 million for the quarter ended June 30, 2020, but relatively
flat versus the quarter ended June 30, 2019, prior to the pandemic.
Net income for the quarter ended June 30, 2021 was $4.4 million, or
$0.22 diluted per share, compared to net income of $7.8 million, or
$0.39 diluted per share, for the same quarter the prior year, and
$5.3 million or $0.26 for the quarter ended June 30, 2019. During
the quarter ended June 30, 2021 there were one-time charges of
$717,000 related to the CEO’s separation agreement. The Company
also incurred an additional cost of $260,000 related to brand and
marketing consulting fees.
Mendo Akdag, the Company’s CEO, commented: “In
our first quarter of FY 2022, we faced a unique situation. We were
coming off a very strong quarter the previous year that was
primarily driven by increased online buying as a result of the
pandemic causing many stores to close and many vets to be
unavailable. As a result, in the first quarter of FY 2021 consumers
increasingly relied on ecommerce. However, during the most recent
quarter while the pandemic was abating and stores were re-opening,
the advertising market was rapidly recovering with demand driving
up ad prices dramatically. As a result, our advertising spending
delivered fewer ad impressions than in prior years. Because of
this, we believe our advertising spending was less effective in the
most recent quarter in its ability to attract new customers. Ad
prices may revert back to more normal levels as the pandemic
further subsides which may increase the efficiency and
effectiveness of our media spending and thereby continue to help us
gain new customers.”
Mr. Akdag added, "In addition, during the most
recent quarter there was a dramatic increase in veterinary visits
by consumers who were unable to visit their veterinarians during
the pandemic. We believe the increase in veterinary visits was
primarily due to pet owners needing to visit their veterinarians
for their pets’ annual exam and to renew their prescriptions. Since
some pet owners purchase medications directly from their vets
during their veterinary visit, the Company believes this negatively
impacted its sales during the quarter. We would expect to see
stronger reorder sales in the back half of FY 2022, as we
anticipate more prescriptions being renewed."
Gian Fulgoni, Chairman of the Board of
Directors, commented: “We are excited about the Company’s future.
We are already a leader in the online pet medication market, which
has a tremendous long term growth opportunity as pet owners
continue to shift their purchases to ecommerce. The Company is in a
very strong financial position, with over $111 million in cash and
cash equivalents and no debt. We have two new board members on the
slate for the annual shareholders’ meeting this week, who each
bring deep ecommerce and marketing experience to the board, and we
are well underway with our search for a new CEO. Going forward, we
anticipate that the introduction of new media strategies and
value-added services will successfully broaden our customer base.
We will also continue investing in our ecommerce platform to better
service our customers by adding additional features to our website
to further drive sales, like AutoShip & Save, which was
launched on our ecommerce platform last week. Our customers
responded very positively and enrollment in AutoShip & Save was
strong in this first week. We anticipate many more of our reorder
sales will transition to AutoShip & Save by the end of our
fiscal year.”
Finally, the Company would like to acknowledge
its current CEO Mendo Akdag, who will be leaving the Company on
July 30, 2021. The Company is very appreciative of Mendo’s
leadership, vision, and dedication over the past 20 years, and
wishes him the best in his future endeavors.
The Board of Directors declared a quarterly
dividend of $0.30 per share on the Company’s common stock. The
dividend will be payable on August 13, 2021, to shareholders of
record at the close of business on August 6, 2021. The Company
intends to continue to pay regular quarterly dividends; however,
the declaration and payment of future dividends is discretionary
and will be subject to a determination by the Board of Directors
each quarter following its review of the Company’s financial
performance.
This morning at 8:30 A.M. Eastern Time, the
Company will host a conference call to review the quarter-end
financial results. To access the call, which is open to the public,
dial (888) 455-1758 (toll free) or (203) 827-7025. Please call in
ten minutes prior to the scheduled start time. Callers will be
required to supply PETMEDS as the passcode. For those unable to
participate in the live event, the call will be available for
replay from 10:00 A.M. Eastern Time on July 26, 2021 until August
9, 2021 at 11:59 P.M. Eastern Time. To access the replay, call
(866) 360-7718 (toll free) or (203) 369-0170 and enter passcode
5500.
Founded in 1996, PetMed Express is America’s
Most Trusted Pet Pharmacy, delivering prescription and
non-prescription pet medications and other health products for
dogs, cats, and horses at competitive prices direct to the consumer
through its 1-800-PetMeds toll free number and on the Internet
through its website at www.petmeds.com.
This press release may contain “forward-looking”
statements, as defined in the Private Securities Litigation Reform
Act of 1995 or by the Securities and Exchange Commission, that
involve a number of risks and uncertainties, including the
Company’s ability to meet the objectives included in its business
plan. Important factors that could cause results to differ
materially from those indicated by such “forward-looking”
statements are set forth in Management’s Discussion and Analysis of
Financial Condition and Results of Operations in the PetMed Express
Annual Report on Form 10-K for the year ended March 31, 2021. The
Company’s future results may also be impacted by other risk factors
listed from time to time in its SEC filings, including, but not
limited to, the Company's Form 10-Q and its Annual Report on Form
10-K.
For investment relations contact PetMed Express,
Inc., Bruce S. Rosenbloom, CFO, 561-526-4444.
PETMED EXPRESS, INC. AND SUBSIDIARIES |
CONDENSED CONSOLIDATED BALANCE SHEETS |
(In thousands, except for per share amounts) |
|
|
June 30, |
|
March 31, |
|
|
2021 |
|
2021 |
|
|
|
|
|
ASSETS |
|
(UNAUDITED) |
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
Cash and cash equivalents |
$ |
111,786 |
$ |
118,718 |
Accounts receivable, less allowance for doubtful accounts of $33
and $39, respectively |
|
2,162 |
|
2,587 |
Inventories - finished goods |
|
29,174 |
|
34,420 |
Prepaid expenses and other current assets |
|
4,061 |
|
4,503 |
Prepaid income taxes |
|
- |
|
959 |
Total current assets |
|
147,183 |
|
161,187 |
|
|
|
|
|
Noncurrent assets: |
|
|
|
|
Property and equipment, net |
|
25,280 |
|
25,450 |
Intangible assets |
|
860 |
|
860 |
Total noncurrent assets |
|
26,140 |
|
26,310 |
|
|
|
|
|
Total assets |
$ |
173,323 |
$ |
187,497 |
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
Accounts payable |
$ |
24,714 |
$ |
39,548 |
Accrued expenses and other current liabilities |
|
6,579 |
|
5,387 |
Income taxes payable |
|
569 |
|
- |
Total current liabilities |
|
31,862 |
|
44,935 |
|
|
|
|
|
Deferred tax liabilities |
|
1,114 |
|
1,281 |
|
|
|
|
|
Total liabilities |
|
32,976 |
|
46,216 |
|
|
|
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
Shareholders' equity: |
|
|
|
|
Preferred stock, $.001 par value, 5,000 shares authorized; 3
convertible shares issued and outstanding with a liquidation
preference of $4 per share |
|
9 |
|
9 |
Common stock, $.001 par value, 40,000 shares authorized; 20,270 and
20,269 shares issued and outstanding, respectively |
|
20 |
|
20 |
Additional paid-in capital |
|
7,829 |
|
7,111 |
Retained earnings |
|
132,489 |
|
134,141 |
|
|
|
|
|
Total shareholders' equity |
|
140,347 |
|
141,281 |
|
|
|
|
|
Total liabilities and shareholders' equity |
$ |
173,323 |
$ |
187,497 |
PETMED EXPRESS, INC. AND
SUBSIDIARIES |
CONDENSED CONSOLIDATED STATEMENTS OF
INCOME |
(In thousands, except for per share amounts)
(Unaudited) |
|
|
|
Three Months Ended |
|
|
June 30, |
|
|
2021 |
|
2020 |
|
|
|
Sales |
$ |
79,312 |
$ |
96,204 |
Cost of sales |
|
57,532 |
|
69,419 |
|
|
|
|
|
Gross profit |
|
21,780 |
|
26,785 |
|
|
|
|
|
Operating expenses: |
|
|
|
|
General and administrative |
|
8,041 |
|
7,754 |
Advertising |
|
7,673 |
|
9,033 |
Depreciation |
|
647 |
|
562 |
Total operating expenses |
|
16,361 |
|
17,349 |
|
|
|
|
|
Income from operations |
|
5,419 |
|
9,436 |
|
|
|
|
|
Other income: |
|
|
|
|
Interest income, net |
|
85 |
|
90 |
Other, net |
|
284 |
|
255 |
Total other income |
|
369 |
|
345 |
|
|
|
|
|
Income before provision for income taxes |
|
5,788 |
|
9,781 |
|
|
|
|
|
Provision for income taxes |
|
1,360 |
|
2,013 |
|
|
|
|
|
Net income |
$ |
4,428 |
$ |
7,768 |
|
|
|
|
|
Net income per common
share: |
|
|
|
|
Basic |
$ |
0.22 |
$ |
0.39 |
Diluted |
$ |
0.22 |
$ |
0.39 |
|
|
|
|
|
Weighted average number of
common shares outstanding: |
|
|
|
|
Basic |
|
20,109 |
|
19,984 |
Diluted |
|
20,200 |
|
20,042 |
|
|
|
|
|
Cash dividends declared per
common share |
$ |
0.30 |
$ |
0.28 |
PETMED EXPRESS, INC. AND SUBSIDIARIES |
CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS |
(In thousands) (Unaudited) |
|
|
Three Months Ended |
|
|
|
June 30, |
|
|
|
2021 |
|
|
2020 |
|
|
|
|
|
|
|
|
Cash flows from operating
activities: |
|
|
|
|
|
|
Net income |
$ |
4,428 |
|
$ |
7,768 |
|
Adjustments to reconcile net income to net cash provided by
operating activities: |
|
|
|
|
|
|
Depreciation |
|
647 |
|
|
562 |
|
Share based compensation |
|
718 |
|
|
740 |
|
Deferred income taxes |
|
(167 |
) |
|
(255 |
) |
Bad debt expense |
|
29 |
|
|
33 |
|
(Increase) decrease in operating assets and increase (decrease) in
liabilities: |
|
|
|
|
|
|
Accounts receivable |
|
396 |
|
|
1,100 |
|
Inventories - finished goods |
|
5,246 |
|
|
(25,187 |
) |
Prepaid income taxes |
|
959 |
|
|
- |
|
Prepaid expenses and other current assets |
|
442 |
|
|
(737 |
) |
Accounts payable |
|
(14,834 |
) |
|
1,317 |
|
Accrued expenses and other current liabilities |
|
1,145 |
|
|
903 |
|
Income taxes payable |
|
569 |
|
|
2,554 |
|
Net cash used in operating
activities |
|
(422 |
) |
|
(11,202 |
) |
|
|
|
|
|
|
|
Cash flows from investing
activities: |
|
|
|
|
|
|
Purchases of property and equipment |
|
(477 |
) |
|
(145 |
) |
Net cash used in investing
activities |
|
(477 |
) |
|
(145 |
) |
|
|
|
|
|
|
|
Cash flows from financing
activities: |
|
|
|
|
|
|
Dividends paid |
|
(6,033 |
) |
|
(5,594 |
) |
Net cash used in financing
activities |
|
(6,033 |
) |
|
(5,594 |
) |
|
|
|
|
|
|
|
Net decrease in cash and cash
equivalents |
|
(6,932 |
) |
|
(16,941 |
) |
|
|
|
|
|
|
|
Cash and cash equivalents, at
beginning of year |
|
118,718 |
|
|
103,762 |
|
|
|
|
|
|
|
|
Cash and cash equivalents, at
end of year |
$ |
111,786 |
|
$ |
86,821 |
|
|
|
|
|
|
|
|
Supplemental disclosure of
cash flow information: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends payable in accrued expenses |
$ |
245 |
|
$ |
297 |
|
PetMed Express (NASDAQ:PETS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
PetMed Express (NASDAQ:PETS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024